Published in Cancer Res on October 15, 2001
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol (2004) 1.39
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res (2010) 1.21
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy. Carcinogenesis (2012) 1.06
Posttranscriptional regulation of p53 and its targets by RNA-binding proteins. Curr Mol Med (2008) 1.03
Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structures. J Am Chem Soc (2008) 0.98
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction. Oncogene (2012) 0.92
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One (2013) 0.90
Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am (2014) 0.85
The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol (2011) 0.84
Reestablishment of p53/Arf and interferon-β pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death. Cell Death Discov (2017) 0.82
Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition. J Org Chem (2014) 0.82
The impact of cellular senescence in cancer therapy: is it true or not? Acta Pharmacol Sin (2011) 0.81
Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer (2010) 0.81
Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatol (2012) 0.81
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells. Oncotarget (2015) 0.80
The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction. Nat Prod Rep (2009) 0.80
Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor. ACS Med Chem Lett (2014) 0.79
SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers. BMC Med Genet (2015) 0.77
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
p53 regulation by TRP2 is not pervasive in melanoma. PLoS One (2014) 0.75
Chemotherapy Resistance Mechanisms in Advanced Skin Cancer. Oncol Rev (2017) 0.75
Modulation of the p53 family network by RNA-binding proteins. Transl Cancer Res (2016) 0.75
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13
Romantic love conceptualized as an attachment process. J Pers Soc Psychol (1987) 7.12
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71
Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol (2001) 2.69
Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell (1996) 2.66
Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci U S A (1999) 2.58
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst (1998) 2.39
Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc Natl Acad Sci U S A (1981) 2.33
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem (1999) 2.21
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med (1997) 2.21
Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest (2001) 2.20
Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell (1998) 2.18
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene (2011) 2.10
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol (1987) 2.04
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
Increased incidence of malignant melanoma after peaks of sunspot activity. Lancet (1978) 1.96
Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer (2009) 1.93
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91
Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Expression of ras proto-oncogene proteins in normal human tissues. Oncogene (1987) 1.86
Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem (2000) 1.85
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 1.82
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Expectation and anticipation of dynamic visual events by 3.5-month-old babies. Child Dev (1988) 1.78
Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Biol Chem (2001) 1.76
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res (2000) 1.75
Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus: a clinicopathologic study of 10 cases on the spectrum of so-called 'malignant blue nevus'. Am J Surg Pathol (2001) 1.75
Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol (2001) 1.73
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res (1998) 1.68
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst (1999) 1.63
Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene. Proc Natl Acad Sci U S A (1991) 1.63
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (1997) 1.62
Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor: report of 16 cases. Am J Surg Pathol (1999) 1.60
Intravenous basic fibroblast growth factor protects the lung but not mediastinal organs against radiation-induced apoptosis in vivo. Cancer J Sci Am (2006) 1.56
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55
Desmoid fibromatosis is a clonal process. Hum Pathol (1996) 1.54
Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst (1994) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res (1994) 1.50
p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci U S A (1999) 1.48
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res (2000) 1.48
Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem (1994) 1.47
Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol (1985) 1.46
Mzf1 controls cell proliferation and tumorigenesis. Genes Dev (2001) 1.43
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med (1989) 1.42
Pupil size and reaction during functional endoscopic sinus surgery (FESS). Clin Otolaryngol Allied Sci (2003) 1.42
Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med (1990) 1.38
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res (1991) 1.36
Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines. Cancer Res (1986) 1.36
Efficient in vivo microRNA targeting of liver metastasis. Oncogene (2010) 1.36
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene (1989) 1.30
Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst (1998) 1.28
The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc Natl Acad Sci U S A (2000) 1.27
Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci U S A (1995) 1.26
Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst (1994) 1.26
Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol (1995) 1.26
Malignant eccrine spiradenoma (spiradenocarcinoma): a clinicopathologic study of 12 cases. Am J Dermatopathol (2000) 1.25
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res (1985) 1.24
High-molecular-weight glycoproteins of human teratocarcinoma defined by monoclonal antibodies to carbohydrate determinants. Cancer Res (1985) 1.24
Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res (2012) 1.23
Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry. Br J Dermatol (2005) 1.23
p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol (1994) 1.22
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res (1999) 1.20
Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol (1999) 1.18
Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res (2000) 1.16
Total plasma creatinine: an accurate measure of total striated muscle mass. J Appl Physiol Respir Environ Exerc Physiol (1981) 1.15